Oxytocin Pharmacokinetics and Pharmacodynamics Study

This study is looking at how oxytocin, a medicine used to help the uterus contract after childbirth, works in the body. Specifically, it's studying deuterated oxytocin (d5OT) in women having a non-emergency C-section. Researchers want to understand how the body processes d5OT (pharmacokinetics) and how different levels of oxytocin in the blood affect uterine contractions (pharmacodynamics). This information could help improve how oxytocin is used to prevent or treat heavy bleeding after delivery (postpartum hemorrhage). The study aims to enroll 100 women between 18 and 50 years old who are having a scheduled or unscheduled C-section.

Study design
This is an interventional study with an enrollment of 100 participants. It is not specified if it is randomized, blinded, or what phase it is in.
What's involved
You would have an extra IV inserted for blood draws during your C-section. Blood samples will be taken at several time points after receiving deuterated oxytocin and standard oxytocin, and uterine tone will be measured.
Compensation
Not stated in the trial record.
Follow-up
Blood samples and uterine tone measurements will be taken for up to 60 minutes after the study drug is given.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05488457

Oxytocin Pharmacokinetics and Pharmacodynamics

Recruiting
PHASE2Ages 18–50InterventionalPrevention
Stanford University
~100 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:deuterated oxytocin (d5OT)

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Baseline plasma concentrations of deuterated oxytocin
Measured over Intraoperatively (prior to delivery)
+19 more outcomes measured
Post Partum Hemorrhage
Cesarean Section Complications
Blood Loss
2 sites across 2 states
California1
Illinois1
  • Naida M Cole, MD · PRINCIPAL_INVESTIGATOR · University of Chicago

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-50 years old
intrauterine pregnancy
term (\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy
non-emergent (scheduled or unscheduled) cesarean delivery

Exclusion

allergy or contraindication to oxytocin
inability to provide informed consent
  • Baseline plasma concentrations of deuterated oxytocinIntraoperatively (prior to delivery)

    The plasma concentration of deuterium labelled oxytocin at baseline

  • Plasma concentrations of deuterated oxytocin at 1 minuteIntraoperatively (1 minute following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 1 minute post-study drug

  • Plasma concentrations of deuterated oxytocin at 2.5 minutesIntraoperatively (2.5 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 2.5 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 5 minutesIntraoperatively (5 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 5 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 10 minutesIntraoperatively (10 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 10 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 15 minutesIntraoperatively (15 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 15 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 20 minutesIntraoperatively (20 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 20 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 30 minutesIntraoperatively (30 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 30 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 45 minutesIntraoperatively (45 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 45 minutes post-study drug

  • Plasma concentrations of deuterated oxytocin at 60 minutesIntraoperatively (60 minutes following study drug administration)

    The plasma concentration of deuterium labelled oxytocin at 60 minutes post-study drug

  • 0-10 Uterine Tone ScoreIntraoperatively (at the time of study drug administration)

    Uterine tone will be ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (1 minute following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (2.5 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (5 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (10 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (15 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (20 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (30 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (45 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.

  • 0-10 Uterine Tone ScoreIntraoperatively (60 minutes following study drug administration)

    Uterine tone ranked by the obstetrician on a 0-10 scale by palpation of the uterus. A score of 0 will represent 'no tone' and a score of 10 will represent 'perfect tone'. The relationship between plasma concentrations and clinical effect will be determined for pharmacodynamic modeling.